Transthyretin-related Familial Amyloid Polyneuropathy: A Case Report

1 Planté-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol. 2011;10(12):1086-97. https://doi.org/10.1016/S1474-4422(11)70246-0 PMid:22094129 Search in Google Scholar

2 Adams D, Beaudonnet G, Adam C, Lacroix C, Théaudin M, Cauquil C, et al. Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment?. Rev Neurol. 2016;172(10):645-52. https://doi.org/10.1016/j.neurol.2016.08.007 PMid:27663057 Search in Google Scholar

3 Nuvolone M, Obici L, Merlini G. Transthyretin-associated familial amyloid polyneuropathy-current and emerging therapies. US Neurol. 2012;8:24-32. https://doi.org/10.5167/uzh-69213 Search in Google Scholar

4 Escolano-Lozano F, Barreiros AP, Birklein F, Geber C. Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis. Brain Behav. 2018;8(1):e00889. https://doi.org/10.1002/brb3.889 PMid:29568686 Search in Google Scholar

5 Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol. 2005;62(7):1057-62. https://doi.org/10.1001/archneur.62.7.1057 PMid:16009758 Search in Google Scholar

6 Shrestha S, Munakomi S. Gower sign. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK540973 [Last accessed on 2023 Feb 13]. Search in Google Scholar

7 Dugo K, Bruno F, Sturiale V, Brancato D, Saccone S, Federico C. Hereditary transthyretin-related amyloidosis: Genetic heterogeneity and early personalized gene therapy. Biomedicines. 2022;10(10):2394. https://doi.org/10.3390/biomedicines10102394 PMid:36289657 Search in Google Scholar

8 Takei YI, Ikeda SI, Ikegami T, Hashikura Y, Miyagawa SI, Ando Y. Ten years of experience with liver transplantation for familial amyloid polyneuropathy in Japan: Outcomes of living donor liver transplantations. Intern Med. 2005;44(11):1151-6. https://doi.org/10.2169/internalmedicine.44.1151 PMid:16357452 Search in Google Scholar

9 Parman Y, Adams D, Obici L, Galán L, Guergueltcheva V, Suhr OB, et al. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: Where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP. Curr Opin Neurol. 2016;29(Suppl 1):S3-13. https://doi.org/10.1097/WCO.0000000000000288 PMid:26734951 Search in Google Scholar

10 Obi CA, Mostertz WC, Griffin JM, Judge DP. ATTR epidemiology, genetics, and prognostic factors. Methodist Debakey Cardiovasc J. 2022;18(2):17-26. https://doi.org/10.14797/mdcvj.1066 PMid:35414855 Search in Google Scholar

11 Conceição I, González-Duarte A, Obici L, Schmidt HH, Simoneau D, Ong ML, et al. “Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy. J Peripher Nerv Syst. 2016;21(1):5-9. https://doi.org/10.1111/jns.12153 PMid:26663427 Search in Google Scholar

12 Planté-Bordeneuve V, Gorram F, Salhi H, Nordine T, Ayache SS, Le Corvoisier P, et al. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: A clinical and neurophysiological study. J Neurol. 2017;264:268-76. https://doi./org/10.1007/s00415-016-8337-3 PMid:27878441 Search in Google Scholar

13 Scott LJ. Tafamidis: A review of its use in familial amyloid polyneuropathy. Drugs. 2014;74(12):1371-8. https://doi.org/10.1007/s40265-014-0260-2 PMid:25022953 Search in Google Scholar

14 Adams D, Suhr OB, Hund E, Obici L, Tournev I, Campistol JM, et al. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy. Curr Opin Neurol. 2016;29(Suppl 1):S14-26. https://doi.org/10.1097/WCO.0000000000000289 PMid:26734952 Search in Google Scholar

15 Merlini G, Coelho T, Waddington Cruz M, Li H, Stewart M, Ebede B. Evaluation of mortality during long-term treatment with tafamidis for transthyretin amyloidosis with polyneuropathy: Clinical trial results up to 8.5 years. Neurol Ther. 2020;9(1):105-15. https://doi.org/10.1007/s40120-020-00180-w PMid:32107748 Search in Google Scholar

16 Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11-21. https://doi.org/10.1056/NEJMoa1716153 PMid:29972753 Search in Google Scholar

17 Michalon A, Hagenbuch A, Huy C, Varela E, Combaluzier B, Damy T, et al. A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. Nat Commun. 2021;12(1):3142. https://doi.org/10.1038/s41467-021-23274-x PMid:34035264 Search in Google Scholar

18 Tschöpe C, Elsanhoury A. Treatment of transthyretin amyloid cardiomyopathy: The current options, the future, and the challenges. J Clin Med. 2022;11(8):2148. https://doi.org/10.3390/jcm11082148 PMid:35456241 Search in Google Scholar